Welcome to
Chemical Collective

Are you 18 or older?

Please confirm that your are 18 years of age or older.

You are not allowed to access the page.

I am 18+

EXIT

SALE NOW ON!

PSYCH NEWS – 14/07/2025

By David Blackbourn

By David Blackbourn

Disclaimer: The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Chemical Collective or any associated parties.

Positive developments in the UK this week as significant strides are made in the push to develop guidelines to standardise research practices for psychedelic trials. The surprising association of the conservative Trump government with the relaxation of the regulation of psychedelics continues as lawmakers back promising new MDMA and psilocybin therapies. Conversely, regulators in the U.S. continue their attempts to close legal loopholes around synthetic cannabinoids, as a result of the 2018 Farm Bill. New data from a phase 3 trial into psilocin for the treatment of depression is showing some cautiously optimistic results, while additional research into psilocin is even showing the potential to reverse the ageing process. Finally, stark contrasts in the business sector, as Compass Pathways stocks plummet, while Lykos Therapeutics successfully secured a further $50 million in funding.

The ReSPCT Guidelines. The GOLD STANDARD for Psychedelic Trials

A study, published in Nature, headed by researchers at the University of Exeter, McGill University, and Imperial College London, is pushing for a holistic approach to clinical research into psychedelics, which stresses the importance of the context of the experience.

This is an area we are, of course, extremely familiar with at Chemical Collective, as regular readers and fellow psychonauts, we hope you are equally familiar with what we know as “Set and Setting”. Integrating this into a clinical/research framework is long overdue, paramount to positive experiences and will go a long way to furthering psychedelics’ acceptance as potential therapeutic aids.

The combined team has developed what they have dubbed: ReSPCT (Reporting of Setting in Psychedelic Clinical Trials). The study aimed to:

Generate consensus-based guidelines for reporting settings in psychedelic clinical research… [because] Psychedelic substances exhibit complex interactions with the ‘set and setting’ of use, that is, the mental state of the user and the environment in which a psychedelic experience takes place. Despite these contextual variables’ known importance, psychedelic research has lacked methodological rigor in reporting extra-pharmacological factors.

Simply put, psychedelic therapy and research have not taken “set and setting” into account in a systematic, coherent manner, even though we are eminently aware of its importance and effects on the experience.

A total of 89 experts from 17 countries independently listed factors they considered important in psychedelic settings. The 770 responses were first refined into 49 distinct items. These were then given a rating – unimportant, important, very important, etc. These refined results were debated and further finalised into the 30 variables considered paramount to a successful experience.

I am aware this is a news article, and I know it’s a lot to take in, but I feel these considerations are worth including in full, all the same:

Item	Item Number	Item Details
Physical Environment
Location	1	Location of the trial, and whether indoors/outdoors and urban/rural/suburban.
Ambiance	2	Room ambiance curated by the study team.
Access to nature	3	Sources of nature or natural elements accessible to participants.
Objects and decorations	4	Objects and decorations in the room.
Lighting	5	Room lighting and adjustability.
Sensory reduction	6	Sensory reduction used, such as headphones and eyeshades.
Bathroom facilities	7	Level of bathroom accessibility, privacy, and safety.
Dosing Session Procedure
Number and roles of people present	8	Number and roles of people present, including participants, study staff, and informal support.
Positioning	9	Relative position of people in the room, and what participants were positioned on.
Focus and main activities	10	Focus (internal or external) and main activities of the dosing session.
Music or soundscapes	11	Music or soundscapes that accompanied the dosing experience.
Interpersonal interventions	12	Verbal or physical interpersonal interventions used throughout the session.
Participant autonomy, control, and agency	13	Level of participant control and agency over activities and environment of the dosing session.
Dosing regimen	14	Dosing regimen, including drug dose(s), frequency, and length of the session.
Medical and experimental procedures or assessments	15	Medical and experimental procedures performed during the session.
Pre- and post-dosing protocol	16	Activities before and after dosing, including participant arrival and release conditions.
Potential disturbances or interruptions	17	Disturbances that may have impacted the dosing session.
Therapeutic Framework and Protocol
Therapeutic or guiding approach	18	Therapeutic or guiding approach used throughout the study, if any, with the accompanying manual or protocol.
Narrative framing	19	Framing of the trial intervention by the study team, including the short- and long-term drug effects.
Number of sessions	20	Number and length of preparation, dosing, and integration sessions.
Preparation protocol	21	Activities performed during the preparation sessions.
Integration protocol	22	Activities performed during the integration sessions.
Additional support or follow-up	23	Formal or informal support or follow-up offered to participants after the end of the trial, including in the case of adverse events.
Study personnel qualifications	24	The credentials, training, and expertise of personnel providing the study intervention or care.
Cultural competence and safety	25	Study team’s level of cultural competence and efforts towards cultural safety.
Subjective Experiences
Therapeutic alliance	26	Therapeutic alliance between participants and facilitators throughout the intervention.
Trust	27	Participant’s level of trust throughout the intervention.
Physical comfort	28	Participant’s level of physical comfort during the dosing session.
Physical safety	29	Participant’s sense of physical safety during the dosing session.
Psychological and cultural safety	30	Participant’s sense of psychological and cultural safety with the people present during the dosing session.

As you can see, there are many factors here that you, yourself, can consider in a recreational scenario. Here at Chemical Collective, we are heavily focused on encouraging harm reduction and safety when considering using psychedelics, which is why I felt their inclusion was necessary in full.

You can find a complete explanatory document from ReSPCT explaining these 30 factors in full HERE.

MAGA and Psychedelics

The U.S. Republican Party has long been a proponent of the disastrous “Just Say No” movement, but recently its position appears to be evolving considerably. I would posit, perhaps cynically, that the motivation here is more a result of the arrival of capital to the sector, as a result of already thawing social attitudes, rather than a purely wellbeing-focused enterprise. Psychedelics are being pushed as potential mental health treatments, particularly for vulnerable groups like veterans. This has largely been brought about by Health Secretary Robert F. Kennedy Jr. His bullish proposals suggest psychedelic-assisted therapies with substances such as ibogaine and MDMA may be available within a year.

Whether or not this is advisable is debatable. With the recent FDA rejection of Lykos Therapeutics’ psychedelic-assisted PTSD therapy, there are definite, widespread concerns with standards and practices. Regardless, it appears Kennedy, alongside the Make America Healthy Again movement, is actively pushing this ahead. This is quite the cultural U-turn, and one of the more surprising developments of the populism at the heart of the Trump era.

Crackdown on Hemp-Derived THC

Pretty much as soon as the 2018 Farm Bill legalised Hemp in the U.S., entrepreneurs predictably and immediately began pushing the envelope of this potential legal grey area. The 2018 Farm Bill permits:

the production of hemp in the United States, and no longer includes hemp as a controlled substance. Hemp with a tetrahydrocannabinol (THC) level of 0.3% or less on a dry weight basis is [no longer] a controlled substance.

This resulted in the proliferation of hemp-derived intoxicants that slip through the wording of this legislation. Chemically modified compounds like Delta-8 THC can still produce psychoactive effects, and now federal agencies and state legislatures are moving aggressively to regulate, restrict, or ban these products outright. This is due to growing concerns over safety and youth access, as well as the more obvious skirting of regulations.

In June, potential language alterations to the bill were raised, which would ban hemp products containing any “quantifiable amounts” of THC, or any other cannabinoid with analogous effects. This would mean pretty much all hemp-based cannabinoid products on the market today could be banned. Even non-intoxicating CBD products would likely be affected by this, as they usually contain trace amounts of THC. While the bill may not be approved in its current format, it does signal the motivations of lawmakers to close this loophole, which will have a large impact and far-reaching implications for the industry as a whole.

A Downturn in Psychedelic Investment

Though psychedelics’ seemingly inevitable push into the mainstream is continuing to pick up pace, 2025 has seen a significant downturn in funding in the sector. Investors are likely cautious due to continued regulatory uncertainty, and clinical results may be less positive than expected. Psychedelics as panacea and potential god-send are, of course, an attractive investment, but with actual results providing positive, but much less compelling data thus far, the market remains uncertain. Compass Pathways provides a stark example. See the change in their stock price over the last 5 years:

On June 23rd this year alone, its stock plummeted 49%, despite Phase-3 results of its latest psilocybin-assisted therapy study successfully hitting its targets. While the trial met its safety and efficacy requirements and Compass Pathways considered the results as both “highly statistically significant” and “clinically meaningful, investors remained unimpressed, which triggered a wider sell-off of psychedelics-related shares.

Bucking this trend, however, Lykos Therapeutics has successfully raised $50 million of additional investment led by billionaires Sir Christopher Hohn and Antonio Gracias. This represents the largest funding round for a psychedelic company in over a year. With the results of widespread trials soon due for release, analysts predict the next 12 months will be critical for the sector’s future success.

Psychedelic Use on the Rise

Most recreational drug use remains low in adolescents and has remained stable at low levels after a drastic drop during the COVID-19 pandemic. However, new data is showing a sharp rise in adult usage of both cannabis and psychedelics, particularly among U.S adults between 19-30.

The Monitoring the Future survey has reported that in 2023, 9% of adults aged 10-30 used hallucinogens in the past year, up from around 5% in 2017 and 3% in 2012. Cannabis use remained at historic highs, with 42% of 19 to 30-year-olds having consumed the drug in the past year.

While the continued rising usage among older populations reflects the growing cultural acceptance of these substances, and I would argue, recreational drug use as a whole, experts warn against potential risks, especially outside of controlled settings. Approximately 40% of users of hallucinogens reported experiencing a “bad trip”, more than likely a result of poor preparation, or poor care and attention to set and setting, and subsequent integration.

A Canadian study even found that individuals who had previously been admitted to ER as a result of psychedelic use were 3.5 times more likely to receive a schizophrenia diagnosis within 3 years.

Much of the limited harm-reduction frameworks we have in place the world over focus on adult treatment. The low rate of adolescent usage is encouraging, suggesting that shifting social norms may lower perceived risks over time anyway, but we cannot lose sight of the fact that education – information freely available and free of scaremongering – is the only way to improve the situation for the future.

Psilocin Shows Anti-Ageing Potential

A study published in NPJ Aging has revealed that psilocin, one of the main active ingredients of magic mushrooms, significantly increases the lifespan of human cells and improves the lifespan of mice. The findings were as follows:

Lifespan extension in mice – A psilocin regimen increased the median survival rate of 19-month-old female mice (19 months chosen to emulate elderly, 60+, humans). The increase in the rate of survival was significant at around 30%.
Improved physical condition in mice – Psilocin-treated mice improve physiologically with healthier fur, reduced greying and improved mobility.
Lifespan extension of human cells – Psilocin treatment extended the growth lifespan of human skin and lung cells by 15-57%, depending on the dosage regimen.

This all sounds exceedingly promising, and potentially very exciting, but we must bear in mind that this is officially preclinical data, so we must temper our expectations somewhat. Perceived effects of substances gained from studies involving mice do not necessarily transfer to human subjects, and the lab context further limits the results’ efficacy in the outside world. To be clear, there are as yet no studies providing concrete evidence that psilocin slows ageing or improves lifespan in human subjects. Safety and appropriate dosage in this scenario are complete unknowns. It is positive, however, to see preliminary results such as these, further signs of psychedelics’ seemingly massive healthcare potential.

David Blackbourn | Community Blogger at Chemical Collective

David is one of our community bloggers here at Chemical Collective. If you’re interested in joining our blogging team and getting paid to write about subjects you’re passionate about, please reach out to Sam via email at samwoolfe@gmail.com

share your toughts

Join the Conversation.

0 Comments

Inline Feedbacks

View all comments

9 minute read

In his book The Weird and the Eerie, cultural theorist Mark Fisher analyses the concept of the 'weird'. Sam Woolfe applies Fisher's analysis to psychedelic states.

09 Feb, 2026

Opinion | Psychedelics and Mark Fisher’s Theory of the Weird

Sam Woolfe

13 minute read

Un aperçu objectif du protoxyde d'azote, examinant sa normalisation croissante, ses effets puissants, son attrait, ses risques et son histoire.

07 Feb, 2026

Guides | Le gaz hilarant : Le protoxyde d’azote (N2O)

Nuit

13 minute read

Nuit compare les expériences de LSA issues de deux sources de semences, contextualisées par l'histoire et la science, dans le but de présenter une vision équilibrée des effets variables, des incertitudes, des risques et des enseignements de la LSA.

05 Feb, 2026

Personal Stories | Le LSA : la version naturelle du LSD ?

Nuit

12 minute read

Stroke, traumatic brain injury, and neurodegenerative diseases are leading, interconnected causes of global disability and economic burden with limited effective treatments. Sam Gandy highlights the potential of psychedelics as novel therapies to promote brain repair and recovery.

03 Feb, 2026

Science | Can Psychedelics Help Mend Broken and Ailing Brains?

Sam Gandy

11 minute read

The ancient, subterranean networks of fungi underpin life on Earth and are now emerging as a powerful foundation for future sustainable biotechnologies.

01 Feb, 2026

Science | Beyond the Trip: How Fungi Are Engineering Our Future

David Blackbourn

8 minute read

Dans la deuxième partie de ce guide sur l'influence du dosage sur les expériences psychédéliques, Eliacide examine les combinaisons de drogues et les expériences qui ne visent pas à dissoudre l'ego.

30 Jan, 2026

Guides | L’influence du dosage sur les expériences psychédéliques (Partie 2)

Eliacide

9 minute read

Eliacide explique que le dosage des médicaments est très subjectif et doit être choisi en fonction du niveau d'expérience personnel et du contexte souhaité, avertissant que les débutants doivent éviter les doses élevées et encourageant les individus à trouver leur propre « juste milieu » plutôt que de considérer tout conseil comme absolu.

28 Jan, 2026

Guides | L’influence du dosage sur les expériences psychédéliques (Partie 1)

Eliacide

9 minute read

Real-world data confirms the extremely low physical risk of psychedelics; the NHS and FDA intensify their scrutiny of clinical rollout; and we see expanding legal momentum in the US, as well as a shift towards shorter-acting compounds and even non-hallucinogenic, virtual alternatives.

26 Jan, 2026

All Articles | PSYCH NEWS – 26/01/2026

David Blackbourn

12 minute read

Nuit s'entretient avec Andrés Gómez, chercheur en conscience à l'Institut de recherche Qualia, qui fait le lien entre la science informatique, les récits expérientiels, les traditions contemplatives orientales et la recherche psychédélique.

25 Jan, 2026

Personal Stories | Mon échange avec le chercheur Andrés Gómez Emilson

Nuit

10 minute read

John Robertson offers a practical guide to understanding the causes of non-responses to psychedelics and what to do to move beyond them safely and effectively.

24 Jan, 2026

Guides | The ‘Nada’ Experience: What To Do When Psychedelics Don’t Work (Part 2)

John Robertson

7 minute read

Alfredo Squillaro argues that informed use, drug checking, and education are far more effective than stigma and repression in reducing the risks of psychoactive substance use.

22 Jan, 2026

Opinion | (Anti)prohibition, Psychonautics, and Designer Drugs

Alfredo Squillaro

11 minute read

Oli Genn-Bash reflects on the Western pursuit of an “authentic self,” using personal psychedelic experiences to question whether self-discovery is less about uncovering a fixed identity and more about cultivating a healthy relationship with the self that allows it to soften, open, and connect with others.

20 Jan, 2026

Self-Development | Discovering the Authentic Self Through Psychedelics

Oli Genn-Bash

9 minute read

Free parties can be understood as modern expressions of ancient ritual practices – akin to the Dionysian Mysteries – where music, dance, and psychoactive substances induce ecstatic states of consciousness.

18 Jan, 2026

Opinion | Dionysian Cults and Free Parties

Alfredo Squillaro

13 minute read

Nuit décrit son expérience du 2C-P comme un psychédélique puissant, à action lente et prolongée, appartenant à la famille des 2C-x – davantage comparable à une longue et exigeante randonnée qu'à un simple voyage.

16 Jan, 2026

Personal Stories | 2C-P : La charrette psychédélique

Nuit

11 minute read

Can psychedelics genuinely challenge and undermine the military-industrial complex by transforming consciousness, or do they risk being co-opted to merely help individuals psychologically adapt to an inherently violent and unjust system?

14 Jan, 2026

Opinion | Decentralised Minds: Can Psychedelics Undermine the Military Industrial Complex?

Oli Genn-Bash

11 minute read

Oli Genn-Bash explores the growing popularity of functional mushrooms, blending personal experience, research, and traditional perspectives to argue for a more holistic, respectful understanding of fungi.

12 Jan, 2026

Opinion | A Holistic and Spiritual Approach to Functional Mushrooms

Oli Genn-Bash

11 minute read

Despite bold promises surrounding psychedelics, a significant share of patients fail to meaningfully improve, revealing that non-response is a central – and often overlooked – challenge in psychedelic therapy.

10 Jan, 2026

Science | Let’s Talk About Non-Responders in Psychedelic Therapy

Ed Prideaux

8 minute read

Psychedelic use is commonly divided into spiritual, therapeutic, and recreational categories whose meanings are unclear and unevenly valued, with recreational use often stigmatised despite having aspects that deserve reconsideration.

08 Jan, 2026

Opinion | In Defence of Recreational Psychedelic Use

Annabelle Abraham

15 minute read

The Immortality Key builds a sweeping psychedelic-religion narrative on evidence that its own primary scientific authority later rejected as methodologically flawed, undermining the book’s credibility despite its popular success.

06 Jan, 2026

History | Psychedelic Bullshit? An Evaluation of The Immortality Key

Ed Prideaux

10 minute read

Over the past year, the psychedelic field has seen unprecedented scientific and regulatory advances collide with bureaucratic barriers and venture capital pressures, revealing both rapid progress toward medical integration and the fragility – and cultural tension – of an emerging industry at a pivotal moment.

04 Jan, 2026

News & Updates | PSYCH NEWS 2025 – THE YEAR IN REVIEW

David Blackbourn

8 minute read

Martha Allitt unpacks the history of MK-ULTRA, a secret CIA program that conducted unethical experiments with LSD, hypnosis, and other techniques in an attempt to develop methods of mind control and psychological manipulation during the Cold War.

04 Jan, 2026

History | MK-ULTRA: A Macabre History of LSD and Mind Control

Martha Allitt

16 minute read

Ed Prideaux examines Elon Musk’s alleged drug use and public behaviour in the context of his immense political and technological influence.

02 Jan, 2026

Opinion | High on Power: How Much Does Ketamine Explain Elon Musk’s Erratic Behaviour?

Ed Prideaux

10 minute read

Psychedelics can help us rethink the “hard problem” of consciousness by challenging the materialist view that the brain generates experience.

30 Dec, 2025

Philosophy | Psychedelics and the Hard Problem of Consciousness

David Blackbourn

12 minute read

Nuit décrit le 2C-C comme un membre subtil et apaisant de la famille 2C-X, qui évoque de doux souvenirs d'expériences sereines et introspectives.

28 Dec, 2025

Guides | 2C-C : la version Stone du 2C-B ?

Nuit

4 minute read

Theories suggest that N,N-dimethyltryptamine (DMT) is released in our brains when we die – but what do we really know about this potent psychedelic and its endogenous role in the human body?

22 Dec, 2025

Science | The Endogenous DMT Narrative: Separating Fact From Fiction

Stephanie Price

11 minute read

While psychedelics get most of the limelight in discussions about altered states of consciousness, such states can also be accessed through more accessible and potentially safer means, particularly sound baths.

20 Dec, 2025

Spirituality | Sound Baths and Altered States

Oli Genn-Bash

9 minute read

David Blackbourn explores the history and present-day use of psychoactive substances in the Middle East, including the religious, social, and political factors that have influenced this usage.

18 Dec, 2025

History | Contemporary Psychoactive Drug Use in the Middle East

David Blackbourn

8 minute read

Iboga, a West African shrub traditionally used in the Bwiti spiritual tradition, is now being used for microdosing in the West.

16 Dec, 2025

Personal Stories | Microdosing Iboga: Why People Are Taking Tiny Amounts of a Hallucinogenic Shrub

Martha Allitt

5 minute read

Clinical trials typically evaluate psychedelics through short-term before-and-after measures to assess treatment efficacy, but longer-term and lifelong effects are harder to quantify.

14 Dec, 2025

Self-Development | The Long-Term Effects of Psychedelics Are Sometimes Ambiguous

Annabelle Abraham

11 minute read

While psychedelic insights may be valuable, they can be difficult to interpret and require a broader psychological, spiritual, philosophical, or cultural framework to determine whether they reflect genuine truth or mere subjective experience.

12 Dec, 2025

Self-Development | Psychedelics and Epistemic Authority: How Can We Trust Psychedelic Insights?

Oli Genn-Bash

Our Products

Related Products

SALE! -35%

1V-LSD 150mcg Blotters From

(145)

1cP-LSD 100mcg Blotters From 18.00

(137)

Tryptamine Mix and Match Pack (4 x 0.1g) €65.00

(1)

SALE! -35%

1V-LSD 10mcg Micro Pellets From

(44)

SALE! -35%

1V-LSD 225mcg Art Design Blotters From

(62)

1S-LSD 150mcg Blotters From 29.00

(18)

1cP-LSD 150mcg Art Design Blotters From 25.00

(74)

SALE! -35%

1V-LSD 225mcg Pellets From

(26)

1cP-LSD 10mcg Micro Pellets From 15.00

(23)

1D-LSD 225mcg Pellets (1T-LSD) From 42.00

(13)

5-MeO-DMT Freebase From 23.95

(36)

1S-LSD 10mcg Micro Pellets €20.00

(3)

O-PCE HCL From 17.50

(25)

1cP-LSD 20mcg Micro Blotters From 18.00

(28)

1cP-LSD 150mcg Pellets From 25.00

(13)

see all products

Earn
Affiliates

Welcome to Chemical Collective.

Create an account to earn 200 welcome points.

create account

Already have an account? Sign in

Comment on an article

50

Check out our Community Blog and get involved with the conversation. You will be awarded 50 x ChemCoins for each comment up to a limit of 250 total ChemCoins.
Leave a product review

50

Have you purchased any of our products? Reviews and reports are so important to the community. Share your honest opinion, and we’ll reward you with 50 ChemCoins for each review!
Complete an order

X

Every time you complete an order with us, you’ll be awarded ChemCoins for each Euro spent.

Welcome to Chemical Collective.

Create an account to earn 200 welcome points.

create account

Already have an account? Sign in

Become an affiliate!

Earn commission every time someone makes a purchase through your link.

When you become an affiliate, you will be allocated a unique link to share with your friends, followers, subscribers, or Aunt Susan.

You can choose to payout the commission earned once per month, or save it up to receive on a rainy day! Commission earned is 5% of the total order value per referral.

Contact us to join the Chemical Collective family and become an affiliate.

Welcome toChemical Collective

PSYCH NEWS – 14/07/2025

By David Blackbourn

in this article

By David Blackbourn

The ReSPCT Guidelines. The GOLD STANDARD for Psychedelic Trials

MAGA and Psychedelics

Crackdown on Hemp-Derived THC

A Downturn in Psychedelic Investment

Psychedelic Use on the Rise

Psilocin Shows Anti-Ageing Potential

By David Blackbourn

share your toughts

Join the Conversation.

Related articles

Related Products

Reward program

Comment on an article

Leave a product review

Complete an order

Become an affiliate!

Welcome to
Chemical Collective